Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea

• Main Authors: Min-Joo Choi (Author), Shin-On Kang (Author), Jin-Jeong Oh (Author), Seong-Beom Park (Author), Min-Ja Kim (Author), Hee-Jin Cheong (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2018-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

In South Korea, the National Immunization Program offers a 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the elderly; however, the 13-valent pneumococcal conjugate vaccine (PCV13) is not included, and vaccination is not offered to younger, at-risk populations. This study offers a compar...